-
Jan 17, 2023Full-Life Technologies Announces Appointment of Steffen Heeger, MD, PhD, as Chief Medical Officer and Fa Liu, PhD, as Chief Scientific Officer
Full-Life Technologies today announced the appointments of Steffen Heeger, MD, PhD, as Chief Medical Officer (CMO) and Fa Liu, PhD as Chief Scientific Officer (CSO).
Read More -
Nov 29, 2022Full-Life Technologies to Acquire Focus-X Therapeutics, Bolstering Peptide-Focused Radiopharmaceutical Pipeline
Acquisition accelerates Full-Life’s transformation into clinical stage radiopharmaceutical company, leveraging its European-focused Radiotechnology and Development Platform
Read More -
Aug 10, 2022Full-Life Technologies Deepens Radioisotope Technology Expertise with Key Leadership Appointments and the Establishment of a Radioisotope Technology Advisory Board
Shanghai, China & Brussels, Belgium - August 10, 2022 - Full-Life Technologies Co., Ltd. (“Full-Life”) today announced two key appointments to its Radioisotope Technology leadership team and the establishment of a Radioisotope Technology Advisory Boar
Read More -
May 26, 2022Full-Life Technologies Completes $37 Million (USD)Series A Financing to Accelerate Development of its Radiopharmaceutical Pipeline and Radiotechnology Production Platform
Full-Life Technologies (“Full-Life”) today announced it completed a $37 million (USD) Series A financing round to advance the development of its radiopharmaceutical oncology product pipeline and its radiotechnology production platform.
Read More -
Jan 04, 2022Full-Life Technologies Announces Senior Executive Team Appointments
Ravi Chari, Ph.D., appointed Chief Scientific Officer Julie Wu appointed Chief Financial Officer, Philippe van Put appointed General Manager, Europe Lanny Sun appointed Chairman.
Read More